Pfizer Inc. (NYSE:PFE) Stock Holdings Increased by OneAscent Financial Services LLC

OneAscent Financial Services LLC boosted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 44.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,999 shares of the biopharmaceutical company's stock after buying an additional 11,447 shares during the quarter. OneAscent Financial Services LLC's holdings in Pfizer were worth $982,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Nordea Investment Management AB increased its stake in shares of Pfizer by 36.1% in the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock worth $108,002,000 after buying an additional 1,080,822 shares during the last quarter. Parsons Capital Management Inc. RI grew its holdings in Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock worth $7,820,000 after acquiring an additional 159,984 shares in the last quarter. Copley Financial Group Inc. acquired a new stake in shares of Pfizer in the 3rd quarter valued at about $577,000. Zacks Investment Management lifted its position in shares of Pfizer by 10.9% during the third quarter. Zacks Investment Management now owns 2,389,138 shares of the biopharmaceutical company's stock worth $69,142,000 after purchasing an additional 235,243 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Pfizer by 1.6% in the third quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company's stock worth $3,392,342,000 after purchasing an additional 1,855,419 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts have commented on PFE shares. Bank of America reaffirmed a "neutral" rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. UBS Group decreased their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Finally, Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of "Moderate Buy" and a consensus price target of $31.92.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.06% of the stock is currently owned by insiders.

Pfizer Price Performance

Shares of Pfizer stock traded down $0.41 during trading on Thursday, hitting $24.30. The stock had a trading volume of 53,412,700 shares, compared to its average volume of 39,310,365. The business has a fifty day moving average of $25.93 and a two-hundred day moving average of $26.81. Pfizer Inc. has a fifty-two week low of $24.26 and a fifty-two week high of $31.54. The firm has a market cap of $137.79 billion, a P/E ratio of 17.23, a PEG ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's quarterly revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.10 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.